Clinical Trials Logo

Neoplasms, Lung clinical trials

View clinical trials related to Neoplasms, Lung.

Filter by:

NCT ID: NCT05857995 Not yet recruiting - Lung Cancer Clinical Trials

Precision Lung Cancer Survivorship Care Intervention

KYLEADSII
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

NCT ID: NCT05011890 Completed - Lung Cancer Clinical Trials

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

LC-PRO
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate how Moovcare®, a mobile medical application, can be used to monitor Patient-Reported Outcomes (PROs) related to cancer treatment, cancer complications, and cancer relapse in patients with lung cancer. PROs are symptoms directly reported by patients through the completion of a survey. Up to 50 patients undergoing treatment and/or surveillance for new or existing diagnoses of lung cancer at the University of North Carolina's Lineberger Comprehensive Cancer Center will be prospectively enrolled to the use of the mobile medical application Moovcare® for 6 months. Moovcare® is not FDA approved, and its role in improving clinical care is being studied through this research. Moovcare® automatically delivers electronic patient reported outcome (ePRO) surveys on common symptoms experienced by lung cancer patients.

NCT ID: NCT04892342 Recruiting - Neoplasms, Breast Clinical Trials

Study of ESG401 in Adults With Solid Tumors

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

NCT ID: NCT04699188 Recruiting - Lung Cancer Clinical Trials

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-01
Start date: February 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

NCT ID: NCT03713099 Withdrawn - Lung Cancer Clinical Trials

NEUWAVE Flexible Probe Study #2

Start date: July 31, 2020
Phase: N/A
Study type: Interventional

Patients with medically inoperable and operable secondary soft tissue lesion(s) of the lung will have transbronchial microwave ablation performed using cone beam CT for probe guidance and confirmation.

NCT ID: NCT03603652 Terminated - Lung Cancer Clinical Trials

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Start date: June 29, 2018
Phase: N/A
Study type: Interventional

Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologist or thoracic surgeon using CT imaging. Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging. Patients will be followed for one year following the ablation procedure for efficacy and safety.

NCT ID: NCT02673021 Terminated - Lung Cancer Clinical Trials

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

MARK 1A
Start date: June 8, 2016
Phase: N/A
Study type: Interventional

Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

NCT ID: NCT02549638 Recruiting - Lung Cancer Clinical Trials

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

Start date: August 2015
Phase:
Study type: Observational

The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria.

NCT ID: NCT02410603 Completed - Lung Cancer Clinical Trials

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer

Start date: December 2016
Phase:
Study type: Observational

The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).

NCT ID: NCT02370303 Completed - Lung Cancer Clinical Trials

A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System

Start date: August 2014
Phase:
Study type: Observational

The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.